All In Biotech

NDA 212269 · Chiesi

Ferriprox

Deferiprone · Oral · Iron Chelator

Accelerated approvalOrphan

Last checked: Nov 20, 2026Latest source record: Mar 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

May 19, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

64

15 Phase 3, 4 recruiting

FAERS reports

3,286

2,205 serious, 381 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: AGRANULOCYTOSIS AND NEUTROPENIA • FERRIPROX can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis. [see Warnings and Precautions ( 5.1 )] • Measure the absolute neutrophil count (ANC) before starting FERRIPROX therapy and monitor regularly while on therapy. • Interrupt FERRIPROX therapy if neutropenia develops. [see Warnings and Precautions ( 5.1 )] • Interrupt FERRIPROX if infection develops, and monitor the ANC more frequently. [see Warnings and Precautions ( 5.1 )] • Advise patients taking FERRIPROX to report immediately any symptoms indicative of infection. [see Warnings and Precautions ( 5.1 )] WARNING: AGRANULOCYTOSIS AND NEUTROPENIA See full prescribing information for complete boxed warning. • FERRIPROX can cause agranulocytosis that can lead to serious infections and death. Neutropenia may...

What it is approved for

From the label in effect Jan 28, 2026.

FERRIPROX Tablets are indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. Limitation s of Use • Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. FERRIPROX Tablets are an iron chelator indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. ( 1 ) Limitation s of Use Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.

Mechanism: Deferiprone is a chelating agent with an affinity for ferric ions (iron III). Deferiprone binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable at physiological pH.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 30, 2021 Supplement 1 · Efficacy OrphanLabelLetter
  • May 19, 2020 Original approval · Type 5 - New Formulation or New Manufacturer Accelerated approvalOrphanLabelLetterReview
1 products under this application
  • FERRIPROX · DEFERIPRONE 1GM · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Deferiprone" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,187
  • death238
  • sickle cell anaemia with crisis218
  • nausea178
  • agranulocytosis163
  • fatigue149
  • ill-defined disorder147
  • vomiting136
  • neutropenia128
  • pyrexia126
  • prescribed overdose109
  • diarrhoea103

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20062
20072
20086
20097
20105
20118
201216
2013113
201487
2015192
2016138
201792
2018138
2019117
2020124
2021267
2022518
2023349
2024350
2025375
2026378

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ferriprox (Deferiprone)

2024 spending

$3.6M

Beneficiaries

39

267 claims

Per beneficiary

$91,169

$59.94 per unit

View as table
YearSpending
2020$0
2021$774,907
2022$3,753,026
2023$3,680,026
2024$3,555,600

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 170 on PubMed

Sponsor: Chiesi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.